Online inquiry

IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15488MR)

This product GTTS-WQ15488MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15488MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2366MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ7716MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ10575MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ9927MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ13075MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ15496MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ3942MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ10505MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW